Compare Ginkgo Bioworks Holdings Inc (DNA) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Marathon Petroleum Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.29 (market cap $505.73M), while Marathon Petroleum Corp trades at $338.9 (market cap $94.48B). The key difference: Marathon Petroleum Corp is far larger — about 186.8× Ginkgo Bioworks Holdings Inc's market cap, and Marathon Petroleum Corp pays a 1.19% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | MPC | |
|---|---|---|
Market Cap | $505.73M | $94.48B |
Sector | Health | Energy |
52-Week High | $16.14 | $336.42 |
52-Week Low | $5.48 | $159.11 |
Enterprise Value | $607.68M | $121.00B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Marathon Petroleum (MPC) trades at $320.32, up 7.42% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat expectations by 22.1%. The stock is in a bullish technical trend, supported by robust refining margins and disciplined operations. Recent news highlights MPC's advantage from global refining tightness and geopolitical disruptions. Valuation ratios like P/E of 11.67 and P/S of 0.65 suggest potential undervaluation relative to earnings growth.
Outlook remains positive with analyst consensus at Buy (75.76%) and a $332.70 price target, though risks include volatile energy markets and debt levels. Earnings growth and cash returns via dividends and buybacks are key catalysts, but investors should monitor refining margin sustainability and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
